"For decades, the medical community has studied what goes wrong when cancer kills, why certain cancers resist treatment and what goes wrong when patients succumb to disease. But a quieter, more unconventional approach is beginning to gain traction: using advanced technology to study the opposite, why some people survive aggressive cancers far longer than predicted.
What we’re noticing is that this pivot in perspective is gaining momentum across research institutions globally. Instead of focusing solely on tumour progression, scientists are now more keen than ever to analyse statistical “outliers”—patients who, despite dire prognoses, achieve long-term survival in cancers like glioblastoma, metastatic pancreatic cancer, and small cell lung cancer."
Read more
